Chris Bulow

COO & Co-Founder at Resistance

Chris built bioinformatic models of treatment resistant cell populations for two clinical trials during his PhD at Washington University in St. Louis. He built microfluidic organ systems for drug screening at Vanderbilt University. He led CMC, drug product manufacturing, and IND-enableing toxicology studies for a resistance blocking combination therapy.

Links

Previous companies

Vanderbilt University logo
The SyBBURE Searle Undergraduate Research Program logo

Timeline

  • COO & Co-Founder

    Current role